InflaRx Highlights Izicopan's Therapeutic Potential at Kidney Week 2026GlobeNewsWire · 2 days ago
InflaRx N.V. (NASDAQ:IFRX) Stock Has Average Target Price of $7.43Defense World · Oct 16, 2026
InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026GlobeNewsWire · Oct 2, 2026
InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical DevelopmentGlobeNewsWire · Oct 1, 2026
InflaRx to Host Virtual Capital Markets DayGlobeNewsWire · Sep 21, 2026
InflaRx Announces Participation in September Investor ConferencesGlobeNewsWire · Aug 20, 2026InflaRx N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States. The company's focus on C5a stems from its critical role as an inflammatory mediator implicated in the progression of various autoimmune and inflammatory diseases. Its primary product candidate, vilobelimab, is an innovative, first-in-class anti-C5a monoclonal antibody delivered intravenously.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.07 | -$0.11 | Miss |
| May 7, 2026 | -$0.17 | -$0.09 | Beat |
| Mar 19, 2026 | -$0.18 | -$0.17 | Beat |
| Nov 10, 2025 | -$0.16 | -$0.16 | Beat |
| Aug 7, 2025 | -$0.24 | -$0.24 | Beat |
| May 7, 2025 | -$0.18 | -$0.14 | Beat |